Who founded OncoHost?

OncoHost was founded by Yuval Shaked in 2017.

Who are OncoHost's investors?

OncoHost's investors include ALIVE Israel HealthTech Fund, OurCrowd, Blumberg Capital.

How much funding has OncoHost raised?

OncoHost has disclosed $35M raised across 1 of its 4 known rounds.

Where is OncoHost headquartered?

OncoHost is headquartered in Israel, IL.

OncoHost

Israel, IL · Founded 2017 · 43 employees on LinkedIn · 3 known investors

Find your way into OncoHost

Paths you didn't know you had: your email and LinkedIn already hold routes to the OncoHost team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

OncoHost develops the PROphet platform, a precision medicine diagnostic tool combining proteomics, bioinformatics, and machine learning to help oncologists predict patient response to cancer therapies and select optimal treatment. The company serves clinicians and cancer patients worldwide with biomarker-driven insights to overcome treatment resistance.

AI & Machine Learning Biotech Digital Health Medical Devices

Founders & leadership

OncoHost was founded in 2017 by Yuval Shaked.

Yuval Shaked Co-Founder & Chief Scientific AdvisorYuval Shaked is a professor at the Rappaport Faculty of Medicine and Head of the Technion Integrated Cancer Center who co-founded OncoHost, where he serves as Chief Scientific Advisor. His research focuses on host response mechanisms in cancer therapy and he advises multiple pharmaceutical and biotech companies.

Ofer Sharon CEOOfer Sharon is a physician and entrepreneur who has founded multiple life-science and digital-health companies over two decades, with experience in clinical development, market access, and precision-oncology diagnostics. He leads OncoHost, which develops the PROphet platform, a proteomics-based diagnostic tool for predicting cancer treatment response.

Investors · 3

ALIVE Israel HealthTech Fundlisted by ALIVE Israel HealthTech FundSavyon

How we know: ALIVE Israel HealthTech Fund's portfolio page · Not right? Tell us

OurCrowdlisted by OurCrowdJerusalem

How we know: OurCrowd's portfolio page · funding news · Not right? Tell us

Blumberg CapitalreportedMiami · $500K – $5M

How we know: a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

$35M disclosed across 1 of 4 rounds · 2021–2022

Undisclosed amountSeries CMay 2022
Source ↗
$35MraisedMay 2022 · 2 sources
Source ↗
Undisclosed amountSeries BJan 2021
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

OncoHost Raises $35 Million Series C Funding Round to Launch Blood Test That May Rewrite the Standard of Care for Precision Oncologyprnewswire.com · May 2022

Frequently asked questions

What does OncoHost do?: OncoHost develops the PROphet platform, a precision medicine diagnostic tool combining proteomics, bioinformatics, and machine learning to help oncologists predict patient response to cancer therapies and select optimal treatment. The company serves clinicians and cancer patients worldwide with biomarker-driven insights to overcome treatment resistance.
Who founded OncoHost?: OncoHost was founded by Yuval Shaked in 2017.
Who are OncoHost's investors?: OncoHost's investors include ALIVE Israel HealthTech Fund, OurCrowd, Blumberg Capital.
How much funding has OncoHost raised?: OncoHost has disclosed $35M raised across 1 of its 4 known rounds.
Where is OncoHost headquartered?: OncoHost is headquartered in Israel, IL.